Rad9A is required for G2 decatenation checkpoint and to prevent endoreduplication in response to topoisomerase II inhibition.

Autor: Greer Card DA; Cancer Research Institute, Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario K7L 3N6, Canada; Departments of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario K7L 3N6, Canada., Sierant ML; Cancer Research Institute, Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario K7L 3N6, Canada; Departments of Biochemistry, Queen's University, Kingston, Ontario K7L 3N6, Canada., Davey S; Cancer Research Institute, Division of Cancer Biology and Genetics, Queen's University, Kingston, Ontario K7L 3N6, Canada; Departments of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario K7L 3N6, Canada; Departments of Biochemistry, Queen's University, Kingston, Ontario K7L 3N6, Canada; Departments of Oncology, Queen's University, Kingston, Ontario K7L 3N6, Canada. Electronic address: sd13@queensu.ca.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2010 May 14; Vol. 285 (20), pp. 15653-15661. Date of Electronic Publication: 2010 Mar 21.